Tazemetostat
E7438-J081-206
Phase 2 small_molecule completed
Quick answer
Tazemetostat for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma is a Phase 2 program (small_molecule) at Eisai Co., with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eisai Co.,
- Indication
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed